1Meldrum BS. Update on the mechanism of action of antiepileptic drugs[J]. Epilepsia, 1996,37(Suppl 6):S4-11.
2Loscher W. Valprote:a reappraisal of its pharmacodynamic properties and mechanisms of action on[J]. Prog Neurobiol, 1999,58(1):31 -59.
3White HS. Comparative anticonvulsant and mehanistic profile of the established and newer antiepileptic drugs[J]. Epilepsia, 1999,40(Suppl 5):S2- 10.
4Gidal B, Spencer N, Maly M, et al. Valproate- mediated disturbances of hemostasis: relationship to dose and plasma concentration[J]. Neuro logy, 1994,44(8):1418 - 1422.
5Deglado MR, Riela AR, Mills J, et al. Thrombocytopenia secondary to high valproate levels in children with epilepsy[J]. J Child Neurol, 1994,9(3):311 -314.
6Kis B, Szupera Z, Mezei Z, et al. Valproate treatment and platelet function: the role of arachidonate metabolites[J]. Epilepsia, 1999,40(3): 307 - 310.
7Ward MM, Barbaro NM, Laxer KD, et al. Preoperative valproate administration does not increase blood 1oss during temporal lobectomy[J]. Epilepsia, 1996,37(1);98 - 101.
8Verrotti A, Greco R, Matera V, et al. Platelet count and function inchildren receiving sodium valproate[J]. Pediatr Neurol, 1999,21 (3):611-614.
9Tanindi S, Akin R, Koseoglu V, et al. The platelet aggregation in children with epilepsy receiving valproic acid[J]. Thromb Res, 1996,81 (4):471 - 476.
10Tohen M, Castillo J, Baldessarini RJ, et al. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2228 patients at risk[J]. Am J Psychiatry, 1995,152(3):413- 148.
